GEKA Stock Overview
Provides pharmaceutical and personal care products primarily in Mexico and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for GEKA from our risk checks.
Genomma Lab Internacional, S.A.B. de C.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Mex$0.96 |
| 52 Week High | Mex$1.35 |
| 52 Week Low | Mex$0.76 |
| Beta | 0.55 |
| 1 Month Change | -11.11% |
| 3 Month Change | -22.58% |
| 1 Year Change | 15.66% |
| 3 Year Change | -7.69% |
| 5 Year Change | 43.28% |
| Change since IPO | 93.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| GEKA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.5% | 2.1% | 2.4% |
| 1Y | 15.7% | -23.4% | 2.0% |
Return vs Industry: GEKA exceeded the German Pharmaceuticals industry which returned -23.4% over the past year.
Return vs Market: GEKA exceeded the German Market which returned 2% over the past year.
Price Volatility
| GEKA volatility | |
|---|---|
| GEKA Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: GEKA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GEKA's weekly volatility (7%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,614 | Juan Marco Sparvieri | www.genommalab.com |
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
Genomma Lab Internacional, S.A.B. de C.V. Fundamentals Summary
| GEKA fundamental statistics | |
|---|---|
| Market cap | €974.00m |
| Earnings (TTM) | €93.63m |
| Revenue (TTM) | €815.11m |
10.5x
P/E Ratio1.2x
P/S RatioIs GEKA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GEKA income statement (TTM) | |
|---|---|
| Revenue | Mex$18.61b |
| Cost of Revenue | Mex$6.68b |
| Gross Profit | Mex$11.93b |
| Other Expenses | Mex$9.79b |
| Earnings | Mex$2.14b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 30, 2025
| Earnings per share (EPS) | 2.19 |
| Gross Margin | 64.12% |
| Net Profit Margin | 11.49% |
| Debt/Equity Ratio | 55.5% |
How did GEKA perform over the long term?
See historical performance and comparisonDividends
3.5%
Current Dividend Yield37%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 02:59 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genomma Lab Internacional, S.A.B. de C.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Antonio Hernandez Velez Leija | Actinver Case de Bolsa, S.A. de C.V. |
| Benjamin Theurer | Barclays |
| Miguel Ulloa Suárez | BBVA Corporate and Investment Bank |